Telmisartan Teva Pharma

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
26-10-2021
Ciri produk Ciri produk (SPC)
26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
19-06-2015

Bahan aktif:

Telmisartan

Boleh didapati daripada:

Teva B.V.

Kod ATC:

C09CA07

INN (Nama Antarabangsa):

telmisartan

Kumpulan terapeutik:

Agents acting on the renin-angiotensin system

Kawasan terapeutik:

Hypertension

Tanda-tanda terapeutik:

Treatment of essential hypertension in adults.

Ringkasan produk:

Revision: 10

Status kebenaran:

Authorised

Tarikh kebenaran:

2011-10-03

Risalah maklumat

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
TELMISARTAN TEVA PHARMA 20 MG TABLETS
Telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Telmisartan Teva Pharma is and what it is used for
2.
What you need to know before you take Telmisartan Teva Pharma
3.
How to take Telmisartan Teva Pharma
4.
Possible side effects
5.
How to store Telmisartan Teva Pharma
6.
Contents of the pack and other information
1.
WHAT TELMISARTAN TEVA PHARMA IS AND WHAT IT IS USED FOR
Telmisartan Teva Pharma belongs to a class of medicines known as
angiotensin-II receptor antagonists.
Angiotensin II is a substance occurring in the body, which causes your
blood vessels to narrow, thus
increasing your blood pressure. Telmisartan Teva Pharma blocks this
effect of angiotensin II so that the
blood vessels relax, and your blood pressure is lowered.
Telmisartan Teva Pharma is used to treat essential hypertension (high
blood pressure) in adults. ‘Essential’
means that the high blood pressure is not caused by any other
condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead sometimes
to heart attacks, heart or kidney failure, strokes or blindness. There
are usually no symptoms of high blood
pressure before damage occurs. Thus it is important to regularly
measure blood pressure to verify if it is
within the normal range.
Telmisartan Teva Pharma is also used to reduce cardiovascular events
(i.e. heart attack or stroke) in adults
who are at risk becaus
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Telmisartan Teva Pharma 20 mg tablets
Telmisartan Teva Pharma 40 mg tablets
Telmisartan Teva Pharma 80 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Telmisartan Teva Pharma 20 mg tablets
Each tablet contains 20 mg telmisartan.
Telmisartan Teva Pharma 40 mg tablets
Each tablet contains 40 mg telmisartan.
Telmisartan Teva Pharma 80 mg tablets
Each tablet contains 80 mg telmisartan.
Excipients with known effect
Telmisartan Teva Pharma 20 mg tablets
Each tablet contains 21.4 mg sorbitol (E420)
Telmisartan Teva Pharma 40 mg tablets
Each tablet contains 42.8 mg sorbitol (E420)
Telmisartan Teva Pharma 80 mg tablets
Each tablet contains 85.6 mg sorbitol (E420)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Telmisartan Teva Pharma 20 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7458".
Telmisartan Teva Pharma 40 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7459".
Telmisartan Teva Pharma 80 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7460".
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
3
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:
•
manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or peripheral
arterial disease) or
•
type 2 diabetes mellitus with documented target organ damage
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Treatment of essential hypertension
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of 20 mg.
In cases where the target blood 
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 26-10-2021
Ciri produk Ciri produk Bulgaria 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 19-06-2015
Risalah maklumat Risalah maklumat Sepanyol 26-10-2021
Ciri produk Ciri produk Sepanyol 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 19-06-2015
Risalah maklumat Risalah maklumat Czech 26-10-2021
Ciri produk Ciri produk Czech 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Czech 19-06-2015
Risalah maklumat Risalah maklumat Denmark 26-10-2021
Ciri produk Ciri produk Denmark 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 19-06-2015
Risalah maklumat Risalah maklumat Jerman 26-10-2021
Ciri produk Ciri produk Jerman 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 19-06-2015
Risalah maklumat Risalah maklumat Estonia 26-10-2021
Ciri produk Ciri produk Estonia 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 19-06-2015
Risalah maklumat Risalah maklumat Greek 26-10-2021
Ciri produk Ciri produk Greek 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Greek 19-06-2015
Risalah maklumat Risalah maklumat Perancis 26-10-2021
Ciri produk Ciri produk Perancis 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 19-06-2015
Risalah maklumat Risalah maklumat Itali 26-10-2021
Ciri produk Ciri produk Itali 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Itali 19-06-2015
Risalah maklumat Risalah maklumat Latvia 26-10-2021
Ciri produk Ciri produk Latvia 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 19-06-2015
Risalah maklumat Risalah maklumat Lithuania 26-10-2021
Ciri produk Ciri produk Lithuania 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 19-06-2015
Risalah maklumat Risalah maklumat Hungary 26-10-2021
Ciri produk Ciri produk Hungary 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 19-06-2015
Risalah maklumat Risalah maklumat Malta 26-10-2021
Ciri produk Ciri produk Malta 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Malta 19-06-2015
Risalah maklumat Risalah maklumat Belanda 26-10-2021
Ciri produk Ciri produk Belanda 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 19-06-2015
Risalah maklumat Risalah maklumat Poland 26-10-2021
Ciri produk Ciri produk Poland 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Poland 19-06-2015
Risalah maklumat Risalah maklumat Portugis 26-10-2021
Ciri produk Ciri produk Portugis 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 19-06-2015
Risalah maklumat Risalah maklumat Romania 26-10-2021
Ciri produk Ciri produk Romania 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Romania 19-06-2015
Risalah maklumat Risalah maklumat Slovak 26-10-2021
Ciri produk Ciri produk Slovak 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 19-06-2015
Risalah maklumat Risalah maklumat Slovenia 26-10-2021
Ciri produk Ciri produk Slovenia 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 19-06-2015
Risalah maklumat Risalah maklumat Finland 26-10-2021
Ciri produk Ciri produk Finland 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Finland 19-06-2015
Risalah maklumat Risalah maklumat Sweden 26-10-2021
Ciri produk Ciri produk Sweden 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 19-06-2015
Risalah maklumat Risalah maklumat Norway 26-10-2021
Ciri produk Ciri produk Norway 26-10-2021
Risalah maklumat Risalah maklumat Iceland 26-10-2021
Ciri produk Ciri produk Iceland 26-10-2021
Risalah maklumat Risalah maklumat Croat 26-10-2021
Ciri produk Ciri produk Croat 26-10-2021
Laporan Penilaian Awam Laporan Penilaian Awam Croat 19-06-2015

Cari amaran yang berkaitan dengan produk ini